About Neuronoff
Neuronoff is a company based in Santa Clarita (United States) founded in 2013 by Andrew Shoffstall and Manfred Franke. Neuronoff has raised $4.5 million across 4 funding rounds from investors including NIH, HHS and U.S. Department of Defense. The company has 21 employees as of December 31, 2024. Neuronoff offers products and services including Injectrode and External Pulse Generator. Neuronoff operates in a competitive market with competitors including ONWARD, Nalu Medical, Atlantic Therapeutics, Synchron and SpineX, among others.
- Headquarter Santa Clarita, United States
- Employees 21 as on 31 Dec, 2024
- Founders Andrew Shoffstall, Manfred Franke
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Neuronoff, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.5 M (USD)
in 4 rounds
-
Latest Funding Round
$4.5 M (USD), Series A
Oct 08, 2025
-
Investors
NIH
& 2 more
-
Employee Count
21
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Neuronoff
Neuronoff offers a comprehensive portfolio of products and services, including Injectrode and External Pulse Generator.
Needle-based system for neuromodulation to alleviate chronic pain signals.
Delivers electrical signals through skin to modulate nerve pain effectively.
Funding Insights of Neuronoff
Neuronoff has successfully raised a total of $4.5M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $4.5 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Neuronoff
Neuronoff has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and U.S. Department of Defense.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked | |
|
Military forces are provided by the U.S. Department of Defense for national security.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Neuronoff
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Neuronoff
Investment portfolio details for Neuronoff
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Neuronoff
Detailed financials for Neuronoff
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neuronoff Comparisons
Peer comparison for Neuronoff
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Neuronoff
Neuronoff operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ONWARD, Nalu Medical, Atlantic Therapeutics, Synchron and SpineX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutic devices for spinal cord injuries are developed and delivered.
|
|
| Locked | Locked | Locked |
Developer of a neurostimulation system for managing intractable chronic pain
|
|
| Locked | Locked | Locked |
Non-invasive wearable devices for pelvic floor strengthening are developed.
|
|
| Locked | Locked | Locked |
Implantable bioelectronics are developed for neurological condition treatments.
|
|
| Locked | Locked | Locked |
Neuromodulation devices for neurological disorders are developed and offered.
|
Detailed competitors of Neuronoff
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neuronoff
Complete news archive for Neuronoff
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neuronoff
Neuronoff was founded in 2013 and raised its 1st funding round 6 years after it was founded.
Neuronoff is headquartered in Santa Clarita, United States. It is registered at Santa Clarita, California, United States.
Manfred Franke is the current CEO of Neuronoff. They have also founded this company.
Neuronoff is a funded company, having raised a total of $4.5M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Neuronoff is 21.
Developer of a neuromodulation device to restore and improve organ activity. The device Injectrod is a novel injectable metal electrode that is deployed via a small needle for manufacturing the neuromodulation interface inside the body on a variety of anatomical targets. It is an alternative means of treating chronic back pain.
Neuronoff's top competitors include ONWARD, Synchron and Nalu Medical.
Neuronoff offers Injectrode and External Pulse Generator.
Neuronoff has 3 investors. Key investors include NIH, HHS, and U.S. Department of Defense.